Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors

Long-lasting control is rarely achieved with tyrosine kinase inhibitors (TKI) alone in metastatic renal cell carcinoma (mRCC). Our study aimed to investigate the survival outcomes of adding stereotactic body radiotherapy (SBRT) to TKI in mRCC. MATERIALS AND METHODS: From September 2015 to September...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Liru, Liu, Yang, Han, Hui, Liu, Zhuowei, Huang, Sijuan, Cao, Wufei, Liu, Boji, Qin, Zike, Guo, Shengjie, Zhang, Zhiling, Lin, Maosheng, Jiang, Xiaobo, Lin, Chengguang, Li, Yonghong, Yao, Kai, Dong, Pei, Zhou, Fangjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Articles: Genitourinary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6922069/
https://www.ncbi.nlm.nih.gov/pubmed/31651452
http://dx.doi.org/10.1097/COC.0000000000000622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6922069/
https://www.ncbi.nlm.nih.gov/pubmed/31651452
http://dx.doi.org/10.1097/COC.0000000000000622

Ejemplares similares